跳至主要内容
临床试验/NCT05001204
NCT05001204Unknown早期 1 期

68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor

Peking Union Medical College Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
30
试验地点
1
主要终点
Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor

研究概览

简要总结

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in Gastrointestinal stromal tumor(GIST)patients. A single dose of 55.5 to 148 MBq(1.5-4 mCi) of 68Ga-NOTA-RM26 will be injected intravenously. Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection.

详细描述

Rm26 is a bioactive polypeptide containing 9 amino acid residues, which can specifically bind to gastrin releasing peptide receptor (GRPR, BB2 receptor). Previous studies have confirmed that there are a large number of GRPR receptors in human common types of tumors, such as lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, glioma and gastrointestinal tumors. Therefore, the use of various radionuclide labeled gastrin releasing peptide receptor analogues RM26 for tumor targeted imaging and treatment greatly improves the early detection rate of tumor, and has important clinical significance and value in tumor staging, prognosis evaluation and curative effect evaluation.This prospective pilot study investigated the use of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR), for evaluating breast cancer using positron-emission tomography/computed tomography (PET/CT).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients in suspicion of gastrointestinal stromal tumors by CT or ultrasonography,and being able to provide basic information and sign the written informed consent form.

排除标准

  • The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with GRPR binding.

研究组 & 干预措施

68Ga-NOTA-RM26 PET/CT

Experimental

Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.

干预措施: 68Ga-NOTA-RM26 (Drug)

结局指标

主要结局

Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor

时间窗: 1 year

The quantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (suv) of the tracer in Gastrointestinal stromal tumors will be measured.

次要结局

  • Adverse events collection(1 week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验